On the other hand, a previous study has shown that chronic myeloid leukemia (CML)-initiating cells (LICs) express high levels of FBXW7 and are maintained in a quiescent state; interestingly, abrogation of the cell-cycle quiescence through FBXW7 depletion makes LICs more sensitive to imatinib, commonly used to treat CML [22]. Here, FBXW7 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.